Health IT can lead to improved clinical outcomes

Utilization of health information technology (HIT) can improve medical outcomes, according to a study published in the Journal of Medical Internet Research.

HIT has come a long way from its beginnings as a means of assisting financial transactions. In this study, researchers examined current literature to assess the correlation between HIT implementation and its effect on medical outcomes.

Publications from the last five years that defined HIT and its effect on medical outcomes in efficiency and effectiveness were collected from the Cumulative Index of Nursing and Allied Health Literature (CINAHL) and Medical Literature Analysis and Retrieval System Online (MEDLINE). Out of 3,636 papers, 37 were included for analysis in this study.

Results found HIT implementation was linked to at least one improved medical outcome in 81 percent of studies. No statistical evidence was found on a difference in outcomes following HIT implementation in 19 percent of studies.

“A strong majority of the literature shows positive effects of HIT on the effectiveness of medical outcomes, which positively supports efforts that prepare for stage three of meaningful use. This aligns with previous reviews in other time frames,” concluded first author Donald A Redelmeier, MSc, MD, and colleagues.

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.